Bhimani Fardeen, McEvoy Maureen, Chen Yu, Gupta Anjuli, Pastoriza Jessica, Fruchter Shani, Bitan Zachary C, Tomé Wolfgang A, Mehta Keyur, Fox Jana, Feldman Sheldon
Breast Surgery Division, Department of Surgery, Montefiore Medical Center, Montefiore Einstein Comprehensive Cancer Center, Bronx, NY, United States.
Department of Radiation Oncology, Montefiore Medical Center, Montefiore Einstein Comprehensive Cancer Center, Bronx, NY, United States.
Front Oncol. 2024 Sep 24;14:1429326. doi: 10.3389/fonc.2024.1429326. eCollection 2024.
Administering radiation therapy to individuals with intellectual disabilities (ID) and psychiatric patients taking antipsychotics poses challenges, especially with whole breast irradiation (WBI) due to difficulty staying still (DSS). In such scenarios, intraoperative radiotherapy (TARGIT-IORT) provides an alternative. Although prior studies have shown its applicability in special cases where WBI may be contraindicated, there is a paucity of literature emphasizing its role in patients with ID and psychiatric conditions who have DSS. Therefore, our case series aims to highlight the applicability of administering TARGIT-IORT in such patients.
Four breast cancer patients underwent lumpectomy and TARGIT-IORT. Among them, two patients had ID, with one experiencing a decreased range of motion. The other two had psychiatric disorders, including schizophrenia and bipolar disorder, both manifesting involuntary movements and DSS. Three patients had invasive ductal carcinoma (IDC), and one had invasive lobular carcinoma (ILC). All patients undergoing TARGIT-IORT tolerated the procedure well. Notably, none of the patients exhibited evidence of disease on follow-up.
Our study underscores the potential use of TARGIT-IORT as a viable treatment option for breast cancer patients with intellectual and psychiatric disabilities. Unlike traditional EBRT, TARGIT-IORT offers a single radiation dose, addressing challenges associated with compliance or DSS. Our findings demonstrate positive outcomes and tolerance, especially in patients where standard oncologic procedures are difficult to achieve. TARGIT-IORT could also benefit breast cancer patients with concurrent movement disorders like Parkinson's disease and other movement disorders. Nonetheless, future studies are needed to reinforce its applicability for patients with DSS.
对智障人士和服用抗精神病药物的精神病患者进行放射治疗存在挑战,尤其是全乳照射(WBI),因为患者难以保持静止(DSS)。在这种情况下,术中放疗(TARGIT - IORT)提供了一种替代方案。尽管先前的研究表明它在WBI可能禁忌的特殊情况下适用,但缺乏强调其在有DSS的智障和精神疾病患者中的作用的文献。因此,我们的病例系列旨在突出TARGIT - IORT在此类患者中的适用性。
四名乳腺癌患者接受了乳房肿瘤切除术和TARGIT - IORT。其中两名患者有智力障碍,一名患者活动范围减小。另外两名患有精神疾病,包括精神分裂症和双相情感障碍,均表现出不自主运动和DSS。三名患者患有浸润性导管癌(IDC),一名患有浸润性小叶癌(ILC)。所有接受TARGIT - IORT的患者对该手术耐受性良好。值得注意的是,所有患者在随访中均未显示疾病迹象。
我们的研究强调了TARGIT - IORT作为智障和精神残疾乳腺癌患者可行治疗选择的潜在用途。与传统的外照射放疗(EBRT)不同,TARGIT - IORT提供单次辐射剂量,解决了与依从性或DSS相关的挑战。我们的研究结果显示出积极的结果和耐受性,特别是在难以实施标准肿瘤手术的患者中。TARGIT - IORT也可能使患有帕金森病等并发运动障碍和其他运动障碍的乳腺癌患者受益。尽管如此,仍需要进一步研究以加强其在有DSS患者中的适用性。